Land: Ástralía
Tungumál: enska
Heimild: APVMA (Australian Pesticides and Veterinary Medicines Authority)
ALUMINIUM HYDROXIDE; BORDETELLA BRONCHISEPTICA (INACTIVATED CELL FREE EXTRACT; CANINE PARAINFLUENZA VIRUS - INACTIVATED
INTERVET AUSTRALIA PTY LIMITED
vaccine - canine Bordetella(0.05ug/dose) + others
MISC. VACCINES OR ANTI SERA
ALUMINIUM HYDROXIDE MINERAL-ALUMINIUM-BASE Active 3.0 mg/do; BORDETELLA BRONCHISEPTICA (INACTIVATED CELL FREE EXTRACT VACCINE-MICROBIAL Active 0.05 ug/do; CANINE PARAINFLUENZA VIRUS - INACTIVATED VACCINE-VIRAL Active 0.0 Undefined
1 SD Vial; 10 SD Vls; 20 SD Vls; 25 SD Vls; 40 SD Vls; 5 SD Vials; 50 SD Vls; Vial = 1mL
VM - Veterinary Medicine
INTERVET AUSTRALIA
DOG - WITH EXCLUSIONS SEE LABEL
IMMUNOTHERAPY
BORDETELLA BRONCHISEPTICA | CANINE PARAINFLUENZA | CANINE COUGH SYNDROME | INFECTIOUS TRACHEOBRONCHITIS
Poison schedule: 0; Withholding period: WHP: N/A.; Host/pest details: DOG - WITH EXCLUSIONS SEE LABEL: [BORDETELLA BRONCHISEPTICA, CANINE PARAINFLUENZA]; Poison schedule: 0; Withholding period: ; Host/pest details: DOG - WITH EXCLUSIONS SEE LABEL: [BORDETELLA BRONCHISEPTICA, CANINE PARAINFLUENZA]; For the active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus.AVOID USING in dogs receiving corticosteroids and in pregnant bitches.
Registered
2023-07-01
INTERVET AUSTRALIA PTY LIMITED COMPANION KC BIVALENT INACTIVATED VACCINE FOR DOGS COMPANY NAME: PRODUCT NAME: PRODUCT NO: LABEL NAME: COMPANION KC BIVALENT INACTIVATED VACCINE FOR DOGS SIGNAL HEADINGS: FOR ANIMAL TREATMENT ONLY CONSTITUENT STATEMENTS: ACTIVE CONSTITUENTS: Each single dose vial contains (minimum titres): -purified inactivated Bordetella bronchiseptica antigen….0.05 µg -inactivated canine parainfluenza virus………… 10^6TCID50 -aluminium hydroxide (adjuvant)……………3 mg CLAIMS: For the active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus. NET CONTENTS: 1 dose vial (1 mL) 5 single dose vials 10 single dose vials 20 single dose vials 25 single dose vials 40 single dose vials 50 single dose vials DIRECTIONS FOR USE: DIRECTIONS FOR USE: Only healthy dogs possessing normal temperatures should be vaccinated. CONTRAINDICATIONS: CONTRAINDICATIONS: This product should not be used in dogs receiving corticosteroids or in pregnant bitches. SIDE EFFECTS: SIDE EFFECTS Local reactions may occur at inoculation sites in some dogs. DOSAGE AND ADMINISTRATION: DOSAGE AND ADMINISTRATION: Note: The removable label should only be removed after the dose has been given. Under normal circumstances: Primary vaccination: 56441/100839 RLP APPROVED For Official Use Only Inject subcutaneously or intramuscularly 2 doses of vaccine at an interval of 1 month to dogs 6 weeks of age or over. Companion® KC Vaccine is suitable for use as a diluent with Companion® C3. Under severe infectious risk, susceptible puppies may benefit from an early start to the vaccination program (6 weeks of age). Vaccination at 2 to 3 week intervals through until 16 weeks of age may also be appropriate in high risk situations. An annual booster is recommended. GENERAL DIRECTIONS: Due to the interference of maternal antibodies with active immunisation, protection of young puppies can be difficult, especially in infected kennels. Epidemiological conditions and the likely persistence of maternal antibodie Lestu allt skjalið
PRODUCT NAME: COMPANION™ KC BIVALENT INACTIVATED VACCINE FOR DOGS MATERIAL SAFETY DATA SHEET THIS REVISION ISSUED: JULY, 2009 PAGE: 1 OF 5 MATERIAL SAFETY DATA SHEET Issued by: Intervet Australia Pty Limited Phone: 1 800 033 461 (Business Hours) Poisons Information Centre: 13 11 26 from anywhere in Australia, (0800 764 766 in New Zealand) SUBSTANCE: Companion KC Bivalent Inactivated Vaccine for Dogs. TRADE NAME: COMPANION™ KC BIVALENT INACTIVATED VACCINE FOR DOGS PRODUCT CODE: 3975 RECOMMENDED USE: For the active immunisation of dogs against _Bordetella bronchiseptica_ and Canine parainfluenza virus. APVMA NO: 56441 CREATION DATE: November, 2006 THIS VERSION ISSUED: July, 2009 and is valid for 5 years from this date. STATEMENT OF HAZARDOUS NATURE: THIS PRODUCT IS CLASSIFIED AS: Not classified as hazardous according to the criteria of SWA. Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code. RISK PHRASES: Not Hazardous - No criteria found. SAFETY PHRASES: None allocated. SUSDP CLASSIFICATION: None allocated. ADG CLASSIFICATION: None allocated. Not a Dangerous Good under the ADG Code. UN NUMBER: None allocated PHYSICAL DESCRIPTION & COLOUR: Slightly opaque pink liquid. ODOUR: No odour. MAJOR HEALTH HAZARDS: no significant risk factors have been found for this product. INHALATION: SHORT TERM EXPOSURE: Available data indicates that this product is not harmful. However product may be mildly irritating, although unlikely to cause anything more than mild transient discomfort. LONG TERM EXPOSURE: No data for health effects associated with long term inhalation. SKIN CONTACT: SHORT TERM EXPOSURE: Available data indicates that this product is not harmful. It should present no hazards in normal use. In addition product is unlikely to cause any discomfort in normal use. LONG TERM EXPOSURE: No data for health effects associated with long term skin exposure. EYE CONTACT: SHORT TERM EXPOSURE : This product may be mildly irritating to eyes, but is unlikely to cause anything more than mild discomfort wh Lestu allt skjalið